<DOC>
	<DOCNO>NCT01591330</DOCNO>
	<brief_summary>The study evaluate effect different particle size LY2140023 . The study involve four single dose 80 mg LY2140023 take 1 tablet mouth washout period least 3 day dos . This study last approximately 60 day include screening . Screening require within 30 day prior study entry .</brief_summary>
	<brief_title>A Study LY2140023 Healthy Males Females</brief_title>
	<detailed_description />
	<criteria>overtly healthy male female , determine medical history physical examination male participant : agree use reliable method birth control study 3 month follow last dose LY2140023 , agree donate sperm 3 month follow last dose LY2140023 female participant : female participant childbearing potential test negative pregnancy screen agree use reliable method birth control duration study least 3 month last dose LY2140023 female participant nonchildbearing potential i.e . postmenopausal permanently sterile follow hysterectomy , bilateral salpingectomy confirm tubal occlusion ( tubal ligation ) . Postmenopausal define menses least 1 year , plasma follicle stimulate hormone ( FSH ) value &gt; 40 mIU/mL , unless participant take hormone replacement therapy body mass index ( BMI ) 19 32 kg/m^2 , inclusive , time screen clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator venous access sufficient allow blood sample per protocol reliable willing make available duration study willing follow study procedure give write informed consent approve Lilly choose ethical review board ( ERB ) currently enrol , complete discontinue within last 90 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study know allergy LY2140023 , LY404039 , related compound component formulation person previously complete withdrawn study study investigate LY2140023 , previously receive investigational product abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study abnormal blood pressure pulse rate , determine investigator history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data evidence history significant active neuropsychiatric disease increase risk seizure base history : one seizure ( except single simple febrile seizure [ lack focality last less 15 minute , associated central nervous system ( CNS ) infection severe metabolic disturbance ] child age 6 month 5 year ) head trauma loss consciousness postconcussive syndrome within 1 year lifetime history head trauma persistent neurological deficit ( focal diffuse ) uncontrolled migraine transient ischemic attack ( TIA ) within 1 year stroke persistent neurological deficit ( focal diffuse ) , uncontrolled migraine define migraine attack produce headache last 72 hour often accompany associate symptom ( nausea , photophobia , phonophobia ) impair wellbeing disrupt social functioning . TIA define `` ministroke '' cause temporary disturbance blood supply area brain , result sudden , brief decrease brain function CNS infection persistent neurological deficit ( focal diffuse ) brain surgery electroencephalogram ( EEG ) paroxysmal ( epileptiform ) activity ( isolated spike wave , repetitive burst sharp wave , paroxysmal activity , frank seizure , spikewave complex , sharpslow wave complex , locally define ) brain structural lesion , include developmental abnormality , determine examination image study ( except hydrocephalus treat shunt without neurological deficit ) . show evidence history know substance dependence abuse time ( accord Diagnostic Statistical Manual Mental Disorders [ DSMIV ] diagnosis ) regularly use know drug abuse and/or show positive finding urinary drug screen show evidence human immunodeficiency ( HIV ) virus infection and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen woman positive pregnancy test woman lactate intend use overthecounter ( OTC ) prescription medication within 14 day prior dose LY2140023 donate blood 500 mL within 3 month prior screen , plan donate blood within 3 month last dose average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , unwilling stop alcohol consumption 48 hour prior checkin treatment period discharge period ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) clinically significant abnormality neurological examination participant judge prior randomization suicidal risk investigator participant unwilling refrain tobacco nicotinecontaining product Clinical Research Unit ( CRU ) unable abide CRU restriction show evidence pruritus skin exfoliation eosinophil count &gt; 1.5 x 109/L . show evidence active renal disease creatinine clearance ( CrCl ) less 90 mL/min ( calculate CockcroftGault equation ) opinion investigator sponsor , unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>